Company research
enGene Therapeutics Inc.
CIK 1980845Updated Sep 26, 2026
Name history
enGene Holdings Inc. · through Mar 9, 2026
ENGN price & chart
Loading TradingView…
NASDAQ:ENGN on TradingView ↗About the company
enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN ↗
Recent filings
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Costs Associated with Exit or Disposal Activities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 2.05, 5.02
4 filing
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 221,468,000Source | 311,173,000Source | 86,959,000Source |
| Property, Plant and Equipment, NetUSD | 2,477,000Source | 1,169,000Source | 589,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 50,152,000Source | 173,004,000Source | 81,521,000Source |
| Assets, CurrentUSD | 201,391,000Source | 247,362,000Source | 85,440,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,649,000Source | 8,626,000Source | 1,500,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,716,000Source | 1,741,000Source | — |
| Other Assets, NoncurrentUSD | 1,362,000Source | 1,374,000Source | 930,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 53,758,000Source | 38,561,000Source | 14,473,000Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 513,281,000Source | 509,811,000Source | 259,373,000Source |
| Retained Earnings (Accumulated Deficit)USD | -372,032,000Source | -254,730,000Source | -199,588,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -888,000Source | -1,419,000Source | -1,016,000Source |
| Stockholders' Equity Attributable to ParentUSD | 167,710,000Source | 272,612,000Source | 72,486,000Source |
| Additional Paid in Capital, Common StockUSD | 27,349,000Source | 18,950,000Source | 13,717,000Source |
| Liabilities and EquityUSD | 221,468,000Source | 311,173,000Source | 86,959,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 31,979,000Source | 14,661,000Source | 5,257,000Source |
| Operating Lease, Liability, CurrentUSD | 2,014,000Source | 423,000Source | — |
| Accounts Payable, CurrentUSD | 6,688,000Source | 1,411,000Source | 1,156,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,455,000Source | 1,427,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -117,302,000Source | -55,142,000Source | -99,917,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 500,000Source | 300,000Source | 200,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 9,646,000Source | 5,324,000Source | 3,450,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts PayableUSD | 4,942,000Source | 474,000Source | 373,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -99,239,000Source | -48,281,000Source | -24,743,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -25,138,000Source | -125,953,000Source | -318,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,485,000Source | 925,000Source | 318,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,524,000Source | 265,716,000Source | 86,147,000Source |
| Dividends paid | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -122,852,000Source | 91,483,000Source | 61,087,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 81,521,000Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,289,000Source | 1,925,000Source | 1,398,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,000Source | 1,000Source | 1,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 9,646,000Source | 5,324,000Source | 3,450,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | 0Source | — |
| DepreciationUSD | 509,000Source | 323,000Source | 175,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -489,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | 100,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -3,000Source | 6,000Source | 100,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | -22,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | -366,000Source | -3,091,000Source |
| General and Administrative ExpenseUSD | 28,685,000Source | 23,982,000Source | 9,602,000Source |
| Income Tax Expense (Benefit)USD | 0Source | -19,000Source | 17,000Source |
| InterestExpenseNonoperatingUSD | 2,994,000Source | 2,798,000Source | — |
| Investment Income, InterestUSD | 9,426,000Source | 10,413,000Source | 1,117,000Source |
| Net Income (Loss) Attributable to ParentUSD | -117,302,000Source | -55,142,000Source | -99,917,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -117,302,000Source | -55,142,000Source | -104,739,000Source |
| Nonoperating Income (Expense)USD | 5,863,000Source | 7,136,000Source | -73,840,000Source |
| Operating ExpensesUSD | 123,165,000Source | 62,297,000Source | 26,060,000Source |
| Other Nonoperating Income (Expense)USD | -569,000Source | -113,000Source | -129,000Source |
| Payments to Acquire InvestmentsUSD | — | 125,028,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 2,223,000Source | 113,000Source | 44,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating Income (Loss)USD | -123,165,000Source | -62,297,000Source | -26,060,000Source |
| Other Nonoperating Income (Expense)USD | -569,000Source | -113,000Source | -129,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -117,302,000Source | -55,161,000Source | -99,900,000Source |
| Income Tax Expense (Benefit)USD | 0Source | -19,000Source | 17,000Source |
| Net Income (Loss) Attributable to ParentUSD | -117,302,000Source | -55,142,000Source | -99,917,000Source |
| Earnings Per Share, BasicUSD per share | 2.29Source | 1.46Source | 151.22Source |
| Earnings Per Share, DilutedUSD per share | 2.29Source | 1.46Source | 151.22Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 51,119,479Source | 37,782,346Source | 692,609Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 51,119,479Source | 37,782,346Source | 692,609Source |
| Interest Expense (non-operating)USD | 2,994,000Source | 2,798,000Source | — |
| Additional Financial Items | |||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 0Source | 0Source | 0Source |
| Current Income Tax Expense (Benefit)USD | — | -19,000Source | 17,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -489,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | 100,000Source |
| General and Administrative ExpenseUSD | 28,685,000Source | 23,982,000Source | 9,602,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -103,727,000Source | -53,460,000Source | -99,157,000Source |
| Interest ExpenseUSD | — | — | 4,953,000Source |
| Investment Income, InterestUSD | 9,426,000Source | 10,413,000Source | 1,117,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -117,302,000Source | -55,142,000Source | -104,739,000Source |
| Nonoperating Income (Expense)USD | 5,863,000Source | 7,136,000Source | -73,840,000Source |
| Operating ExpensesUSD | 123,165,000Source | 62,297,000Source | 26,060,000Source |
| Other General and Administrative ExpenseUSD | 11,471,000Source | — | — |
| Research and Development ExpenseUSD | 94,480,000Source | 38,315,000Source | 16,458,000Source |
Filing attachments
engn-ex99_1.htm · 8-K · 2026-09-08
EX-99.1 2 engn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 enGene Reports Third Quarter 2026 Financial Results and Provides Business Update Data update on key regulatory endpoints, complete response (CR) at any time and maturing durability, as well as landmark CR rates from LEGEND's pivotal cohort planned for 4Q 2026 Pre-Biologics License Application (BLA) meeting with the FDA on track for 4Q 2026 Initiation of BLA submission for detalimogene planned for 4Q 2026 Detalimogene plus surfactan…
Read attachment ↗engn-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 engn-ex99_1.htm EX-99.1 Non-Viral Genetic Medicine Virtual KOL Event: Emerging NMIBC Market Insights August 11, 2026 Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements may be identified by the use of …
Read attachment ↗engn-ex99_1.htm · 8-K · 2026-07-17
EX-99.1 2 engn-ex99_1.htm EX-99.1 Corporate Presentation Non-Viral Genetic Medicine Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements may be identified by the use of the words such as “forecast”, “intend”, “de…
Read attachment ↗engn-ex99_1.htm · 8-K · 2026-07-16
EX-99.1 2 engn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones Michael Heffernan assumes the role of Chairman of the Board Dr. Richard Glickman to step down Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026 Initiation of BLA submission for detalimogene planned for 2H 2026 Potential FDA approval of detalimogene in 2027 BOSTON & MONTREAL, July 16, 2026 - enGene Therapeutics Inc.…
Read attachment ↗engn-ex99_1.htm · 8-K · 2026-06-15
EX-99.1 2 engn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 enGene Reports Second Quarter 2026 Financial Results and Provides Business Update 12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Application (BLA) filing for detalimogene planned for 2H 2026 First patients enrolled in surfactant plus detalimogene cohort Approximately 50% reduction in force to streamline operations and preserve cash to focu…
Read attachment ↗d335486dex991.htm · 8-K · 2026-05-07
EX-99.1 2 d335486dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 enGene Announces Updated Interim Results From LEGEND Pivotal Cohort 54% complete response (CR) rate at any time; 43% six-month CR rate Low rate of progression to muscle-invasive or higher disease (3.2%) Low percentage of patients experienced treatment-related adverse events (TRAEs) (55%), nearly all of which were mild Low percentage of patients experienced TRAEs leading to treatment interruption (2.4%) or discontinuation (2.4%) …
Read attachment ↗